Trial Profile
A Phase 1/2 Open-Label Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Seviteronel in Subjects With Castration-Resistant Prostate Cancer
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 20 Jan 2022
Price :
$35
*
At a glance
- Drugs Seviteronel (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Adverse reactions; First in man; Therapeutic Use
- Sponsors Innocrin Pharmaceuticals; Viamet Pharmaceuticals
- 31 Jan 2019 Status changed from active, no longer recruiting to completed.
- 28 Feb 2018 Planned End Date changed from 1 Jun 2018 to 1 Dec 2018.
- 28 Feb 2018 Planned primary completion date changed from 1 Dec 2017 to 1 Sep 2018.